Certara Offers TQT Assessment Tool
Product helps to determine whether a drug candidate prolongs cardiac repolarization, a surrogate for potentially-fatal arrhythmias
Certara, which offers software and scientific consulting services for drug development, announced the launch of itsPhoenix QT+ cardiac safety assessment tool. This product provides data processing, statistical, and modeling capabilities in regard to Thorough QT (TQT) study requirements under the ICH E14 Guidelines (ICH, 2005). The product provides a comprehensive analysis of electrocardiogram (ECG) interval data collected in TQT studies and sub-studies in other clinical trials to determine whether a drug is at risk for cardiac depolarization prolongation.
Read the full release here.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
